Atossa Genetics, Inc.

atossagenetics.com

Atossa Genetics Inc. (NASDAQ: ATOS) is developing locally-administered pharmaceuticals for pre-cancerous breast conditions and early stage breast cancer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

MEMED RAISES $93M TO ACCELERATE COMMERCIALIZATION OF ITS HOST IMMUNE-RESPONSE PRODUCT PORTFOLIO

MeMed | January 10, 2022

news image

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

Read More

INDUSTRIAL IMPACT

RIBBON BIOLABS ESTABLISHES IP PORTFOLIO WITH FIRST GRANTED U.S. PATENT COVERING FAST, COST-EFFECTIVE, LONG DNA SYNTHESIS TECHNOLOGY

Ribbon Biolabs | July 20, 2022

news image

Ribbon Biolabs, the DNA synthesis company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs’ novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications to be granted to the company, forming the foundation of its IP portfolio covering its long DNA synthesis technology. “ Read More

OPKO HEALTH ACQUIRES MODEX THERAPEUTICS, GAINS PROPRIETARY IMMUNOTHERAPY TECHNOLOGY WITH A FOCUS ON ONCOLOGY AND INFECTIOUS DISEASES

OPKO Health | May 10, 2022

news image

OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. Founded in October 2020 with headquarters in Natick, Mass., ModeX Therapeutics has developed highly flexible multi-specific antibody t...

Read More

INDUSTRIAL IMPACT

CYCLICA LAUNCHES PERTURBA THERAPEUTICS, A SPIN OUT FROM THE UNIVERSITY OF TORONTO, CREATING THE NEXT-GENERATION ONCOLOGY BIOTECH

Cyclica Inc. | February 10, 2022

news image

Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs). Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Per...

Read More
news image

INDUSTRIAL IMPACT

MEMED RAISES $93M TO ACCELERATE COMMERCIALIZATION OF ITS HOST IMMUNE-RESPONSE PRODUCT PORTFOLIO

MeMed | January 10, 2022

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

Read More
news image

INDUSTRIAL IMPACT

RIBBON BIOLABS ESTABLISHES IP PORTFOLIO WITH FIRST GRANTED U.S. PATENT COVERING FAST, COST-EFFECTIVE, LONG DNA SYNTHESIS TECHNOLOGY

Ribbon Biolabs | July 20, 2022

Ribbon Biolabs, the DNA synthesis company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs’ novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications to be granted to the company, forming the foundation of its IP portfolio covering its long DNA synthesis technology. “ Read More

news image

OPKO HEALTH ACQUIRES MODEX THERAPEUTICS, GAINS PROPRIETARY IMMUNOTHERAPY TECHNOLOGY WITH A FOCUS ON ONCOLOGY AND INFECTIOUS DISEASES

OPKO Health | May 10, 2022

OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. Founded in October 2020 with headquarters in Natick, Mass., ModeX Therapeutics has developed highly flexible multi-specific antibody t...

Read More
news image

INDUSTRIAL IMPACT

CYCLICA LAUNCHES PERTURBA THERAPEUTICS, A SPIN OUT FROM THE UNIVERSITY OF TORONTO, CREATING THE NEXT-GENERATION ONCOLOGY BIOTECH

Cyclica Inc. | February 10, 2022

Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs). Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Per...

Read More